Asset Management One Co. Ltd. Raises Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Asset Management One Co. Ltd. grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.7% during the 1st quarter, HoldingsChannel.com reports. The firm owned 55,872 shares of the company’s stock after buying an additional 3,028 shares during the quarter. Asset Management One Co. Ltd.’s holdings in IDEXX Laboratories were worth $23,463,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Norges Bank purchased a new stake in IDEXX Laboratories in the 4th quarter valued at approximately $412,258,000. GAMMA Investing LLC boosted its holdings in IDEXX Laboratories by 59,810.7% in the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company’s stock valued at $3,856,950,000 after purchasing an additional 916,898 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in IDEXX Laboratories in the 4th quarter valued at approximately $156,412,000. William Blair Investment Management LLC boosted its holdings in IDEXX Laboratories by 701.6% in the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock valued at $174,527,000 after purchasing an additional 369,471 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in IDEXX Laboratories by 221.3% in the 4th quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company’s stock valued at $182,459,000 after purchasing an additional 303,966 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.0%

IDXX opened at $530.40 on Thursday. The business’s fifty day moving average is $494.30 and its two-hundred day moving average is $449.63. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The company has a market cap of $42.66 billion, a price-to-earnings ratio of 49.02, a PEG ratio of 3.87 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $533.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. IDEXX Laboratories’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.71 earnings per share. Analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 1,260 shares of the company’s stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the sale, the director now directly owns 1,801 shares in the company, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.98% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of analyst reports. Morgan Stanley lifted their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a report on Monday, May 5th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Leerink Partners lifted their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, June 11th. Finally, Stifel Nicolaus boosted their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a “hold” rating in a research note on Monday, May 19th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $546.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.